Jefferies Financial Group Forecasts Strong Price Appreciation for aTyr Pharma (NASDAQ:ATYR) Stock

aTyr Pharma (NASDAQ:ATYR) had its price target lifted by analysts at Jefferies Financial Group from $9.00 to $17.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Jefferies Financial Group’s price objective suggests a potential upside of 217.76% from the stock’s previous close.

Several other research analysts also recently weighed in on the stock. Wells Fargo & Company upped their target price on shares of aTyr Pharma from $17.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, June 20th. HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of aTyr Pharma in a research note on Wednesday, June 4th. Finally, Wall Street Zen downgraded shares of aTyr Pharma from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. One equities research analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $23.25.

aTyr Pharma Price Performance

ATYR opened at $5.35 on Friday. The company has a quick ratio of 5.63, a current ratio of 5.63 and a debt-to-equity ratio of 0.01. aTyr Pharma has a 52-week low of $1.67 and a 52-week high of $7.29. The company has a 50 day moving average of $5.30 and a two-hundred day moving average of $4.22. The company has a market cap of $524.25 million, a P/E ratio of -6.69 and a beta of 0.94.

aTyr Pharma (NASDAQ:ATYR) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.04). On average, analysts expect that aTyr Pharma will post -0.91 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ATYR. Point72 Asset Management L.P. bought a new position in aTyr Pharma during the 4th quarter valued at $17,677,000. Octagon Capital Advisors LP boosted its stake in aTyr Pharma by 294.7% during the 1st quarter. Octagon Capital Advisors LP now owns 3,552,000 shares of the company’s stock valued at $10,727,000 after acquiring an additional 2,652,000 shares during the last quarter. Woodline Partners LP bought a new position in aTyr Pharma during the 4th quarter valued at $6,092,000. Alyeska Investment Group L.P. bought a new position in aTyr Pharma during the 4th quarter valued at $4,628,000. Finally, Millennium Management LLC boosted its stake in aTyr Pharma by 334.5% during the 1st quarter. Millennium Management LLC now owns 1,599,041 shares of the company’s stock valued at $4,829,000 after acquiring an additional 1,231,052 shares during the last quarter. 61.72% of the stock is currently owned by institutional investors.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.